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Abstract
Background: The dystrophin gene is the one of the largest described in human beings and mutations associated
to this gene are responsible for Duchenne or Becker muscular dystrophies.
Case Presentation: Here we describe a nucleotide substitution in the acceptor splice site of intron 26 (c.3604-1G >
C) carried by a 6-year-old boy who presented with a history of progressive proximal muscle weakness and elevated
serum creatine kinase levels. RNA analysis showed that the first two nucleotides of the mutated intron 26 (AC) were
not recognized by the splicing machinery and a new splicing site was created within exon 27, generating a
premature stop codon and avoiding protein translation.
Conclusions: The evaluation of the pathogenic effect of the mutation by mRNA analysis will be useful in the optics
of an antisense oligonucleotides (AON)-based therapy.
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Background
Muscular dystrophies include more than 30 inherited
disorders causing muscle to weaken and wither away,
and Duchenne Muscular Dystrophy (DMD) represents
the most severe form of this family of disorders. It is an
X-linked disease, affecting 1 in 5000 male births and is
caused by the absence of the protein dystrophin in skel-
etal, cardiac and smooth muscle. Clinical symptoms
manifest at about 3 years of age, and with the progres-
sive muscle impairment patients are wheelchair bound
by their early teen years and suffer cardiac/respiratory
failure in their mid- to late twenties [1]. In particular,
the incidence of cardiomyopathy in DMD increases with
age. Around 25 % of patients have cardiomyopathy at
6 years of age and 59 % from 10 years of age, in older
patients cardiac involvement is ubiquitous, as more than
90 % of young men over 18 years of age demonstrate
evidence of cardiac dysfunction. No cure is nowadays
available and current treatments include steroid admin-
istration and assisted ventilation [2].
Dystrophin is a cytoplasmatic protein located at the
membrane of muscle fibres (sarcolemma) representing a
connection between the extracellular matrix and the
cytoplasmatic compartment of muscle fibres. For this
reason mechanical stress like contraction during normal
exercise impairs dystrophic muscle fibres that degener-
ate and, as time goes by, non-contractile fibrotic tissue
replaces muscle tissue [1]. Dystrophin, other than having
a mechanical role, takes part in several signalling
pathways spanning from Ca2+ through Nitric Oxide
(NO) synthesis and Ras/MAPK pathway, underling even
more the relevancy of this protein in muscle physiology.
In DMD patients absence of dystrophin is caused by
frameshift mutations in the DMD gene that give origin
to premature stop codons and avoid protein translation.
There are also mutations that maintain the open reading
frame (ORF) of the DMD gene leading to a milder form
of dystrophy called Becker Muscular Dystrophy (BMD).
BMD subjects are in fact characterized by low levels of
full-length dystrophin or carry in-frame mutations that
allow the generation of shorter but functional forms of
dystrophin. The onset of symptoms in BMD subjects is
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usually in late childhood or adolescence, and the course
is slower and less predictable than that of DMD.
The DMD gene is one of the largest in the human
genome (approximately 2.22 million base pairs, encoding
79 exons) and it is characterized by a frequency of muta-
tion > 8 × 10−5 [2] (OMIM; 300376). 65 % of DMD pa-
tients harbour dystrophin gene deletions in a commonly
mutated region including exons 45–55 with genomic
breakpoints (ie, the endpoint of where the deletions ac-
tually occurs) lying within intron 44, and exons 2–19
with genomic breakpoints commonly found in introns 2
and 7 and alsoextending toward the downstream introns
(OMIM; 300376) [3]. The clusters of these two hotspots
represent the basis for the use of the multiplex PCR
technique that, by the screening of only 19 exons, identi-
fies about 98 % of all deletions [4–7]. Nevertheless, the
multiplex PCR has been superseded in many laboratories
by the convenience and commercial availability of multi-
plex ligation-dependent probe amplification (MLPA).
MLPA is a quantitative assay of all exons of the DMD
gene and the use of this technique strongly improves the
mutation detection rate. Before MLPA was used as a
routinely diagnostic tool, in fact, exon duplications
within the DMD gene were estimated to be 5 % of all
mutations responsible for DMD but the use of quantita-
tive assay like MLPA raised this percentage to 10. The
remaining ones are small insertions/deletions or point
mutations and they are identified by direct sequencing
of dystrophin gene. Point mutations also generate spli-
cing defects in the donor/acceptor splice sites that cause
exon skipping, intron retention or activation of cryptic
splice sites within an exon or intron.
Here we describe a 6 year-old boy with a clinical his-
tory of progressive proximal muscle weakness who was
diagnosed with DMD. Our major aim was to identify the
mutation responsible for DMD and understand its
pathogenic effect in order to confirm the clinical diagno-
sis with a molecular mechanism. Identifying the muta-
tion also reduces the risk of recurrence of the disease in
the family and minimize anxiety in the relatives of the
patients. Moreover, understanding its pathogenic effect
highlights the potential therapeutic approaches relevant
for the patient and might help identifying the correlation
between the genotype and the phenotype.
Results and discussion
Case report
The patient was diagnosed with DMD at 3 years of age
on the basis of clinical presentation, elevated serum cre-
atine kinase (CK) (26678 U/L), and negative dystrophin
staining on immunohistochemistry. At the beginning he
developed a sudden appearance of laterocervical tume-
faction, not due to EVC, CMV and toxoplasm infections.
Over the next year he developed troubles playing sports,
climbing stairs and keeping up with peers. Early devel-
opment was normal and he achieved above average aca-
demic performance. He has no affected brother and
sister. On examination at 6 years of age cardiac and gen-
eral exam were normal. Muscle bulk was normal with
the exception of notable enlargement of calf muscles. A
mildly increased lumbar lordosis was also present.
Strength testing using the Medical Research Council
(MRC) grading revealed weakness in the following distri-
bution: femoral quadriceps 4 bilateral, ileopsoas 4- bilat-
eral, tibialis anterior 4/5 bilateral, gastrocnemius 4/5
bilateral, tibialis posterior 4/5 bilateral. He utilized the
Gowers’ manoeuvre to rise from the floor in 6–7 s. He
was able to climb stairs using banister or a person, he
had never been able to run as quickly as his peers and
he showed an ambulation steppage gait. He did not
require ambulatory aids but he showed limited endur-
ance, he was idler and renouncer. Prolonged walking for
greater than 30 min led to muscle discomfort in the calf
muscles, and a brief period of rest was required to elim-
inate the discomfort as well as to alleviate fatigue.
Laboratory studies revealed elevated alanine transamin-
ase (ALT) at 397 U/L and aspartate transaminase (AST)
at 190 U/L, elevated glucose level (121 mg/dl) and low
iron level 56mcg/dl. Serum CK was 11375 U/L. Echocar-
diogram was normal with no evidence of myocardial
hypertrophy.
Immunohistochemistry
Muscle sections of the DMD patient and a control
subject were stained with H&E. Respect muscle of con-
trol muscle (Fig. 1a), dystrophic muscle sections were
characterized by fibres of variable cross sectional area
(CSA), scattered necrotic and regenerating fibres and by
prominent endomysial and perimysial fibrosis (Fig. 1b).
In order to confirm the absence of dystrophin protein
in the patient, muscle sections cut from frozen biceps
brachialis of the DMD patient and healthy subject were
stained for dystrophin (Fig. 1c–d). This analysis evi-
denced the absence of dystrophin protein in muscle of
DMD patient (Fig. 1d). Otherwise, control muscle pre-
sented a normal expression of dystrophin which is
localized under the sarcolemma (Fig. 1c). Moreover,
staining for sarcoglycans evidenced only a marked
down-regulation of alpha-sarcoglycan in dystrophic
patients (data not show).
Mutational analysis
Genomic DNA was isolated from peripheral leukocytes
obtained from the DMD patient. Genomic DNA was an-
alyzed by MLPA using a commercial kit (MRC Holland).
Deletions or duplications of any of the 79 exons in the
dystrophin gene were not detected. Next step was to
scan the DMD gene for nucleotide changes. Numerous
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methods that function as pre-screens can be applied to
this aim, including SSCP [8], dHPLC [9], FM-CSCE [10],
PTT [11] and HR-MCA [12]. Nevertheless, since the
cost of sequencing has reduced dramatically it is more
appropriate to sequence the full gene now [13]. Direct
sequencing of the genomic DNA of the DMD patient
identified a nucleotide substitution (c.3604-1G > C) of
the last nucleotide of intron 26. Searching in DMD mu-
tation database (www.dmd.nl) revealed that this variant
was not described before. This mutation affected the ac-
ceptor splice site AG (3′ splice site) of intron 26. Alamut
2.0 Splicing Prediction Module was used in order to
evaluate the potential consequences of the mutation on
mRNA splicing. According to the online software, the
mutation could induce skipping of exon 27. Neverthe-
less, since skipping of this exon would generate an in-
frame mRNA of the DMD gene, we further investigated
the functional significance of this mutation change. In
this view, we analysed the mRNA isolated from periph-
eral leukocytes of the patient and the control subject. In
particular we focused on the region of the DMD gene
expanding from exon-25 to exon 29. The RT-PCR did
not reveal abnormalities in terms of mRNA length, sug-
gesting a correct splicing (Fig. 2a). Nevertheless, direct
sequencing of the PCR products evidenced that the first
two nucleotides of exon 27 (AG) were absent in the dys-
trophin mRNA of the DMD patient. The elimination of
these two nucleotides from the mRNA shifted the open
reading frame (ORF) of exon 27, generating a premature
stop codon (UAA) and leading to the absence of dys-
trophin protein in the skeletal muscle of the DMD
patient, as confirmed by immunohistochemistry analysis
(Fig. 1). Basing on these evidences, the mechanism pro-
posed is that in the presence of the mutated acceptor
splice site of intron 26 (AC), the first two nucleotides of
intron 27 are recognized as a new acceptor splice site
due to sequence homology and are not included in the
mRNA. The elimination of the first two nucleotides AG
of the exon 27 generates a STOP codon in exon 27 that
does not permit the production of a functional dys-
trophin protein (c).
Conclusions
Here we describe a boy who was diagnosed with DMD
at 3 years of age on the basis of clinical presentation.and
negative dystrophin staining on immunohistochemistry.
Our major aim was to identify the mutation responsible
for the DMD clinical phenotype and its pathogenic effect
on dystrophin translation.
The Best Practice Guidelines for molecular diagnosis
of DMD/BMD established that an initial screen detect-
ing the majority of deletions and duplication must be
the minimum diagnosis offered. This initial screen can
be performed by multiplex PCR technique that screens
only 19 exons, the “hot spot”, allowing the identification
of about 98 % of all deletions. A more efficient and sens-
ible technique is nevertheless represented by MLPA that
allows the quantification of all exons of the DMD gene
Fig. 1 Histological analysis of control and DMD patient. Muscle sections were stained with Hematoxylin-Eosin (a-b). Normal muscle was compared to
dystrophic one (a). The dystrophic muscle presented marked variability in fiber size, fiber splitting, scattered necrotic and regenerating fibers, and
prominent endomysial and perimysial fibrosis (b). Muscle sections cut from normal (c) and dystrophic muscle were stained with dystrophin antibodies
(d) in green. Nuclei were stained with DAPI
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enabling the detection of deletions and duplications at
the same time. In our case, we performed a MLPA ana-
lysis of genomic DNA that evidenced any exon
deletions/duplications. When no exon deletions or du-
plications are found, and results from muscle biopsy
suggest a dystrophinopathy, the clinical diagnosis cannot
be confirmed nor excluded (Abbs S Neuromuscular Dis-
orders 2010). In this case, further tests have to be per-
formed in order to identify the pathogenic mutations,
like gene sequencing. Interestingly when we sequenced
the DMD gene a nucleotide substitution (c.3604-1G > C)
of the last nucleotide of intron 26 was identified. This
mutation affected the acceptor splice site AG (3′ splice
site) of intron 26. When a point mutation is within
splice consensus sequences, aberrant splicing is likely to
happen and maintenance of ORF should be checked by
using splice prediction programmes and by analysis of
the mRNA. Analysis of the DMD gene variant with Ala-
mut 2.0 Splicing Prediction Module predicted that the
mutation could induce skipping of exon 27. Since skip-
ping of this exon would generate an in-frame mRNA of
the DMD gene, we further investigated the pathogenic
effect of this mutation on the DMD gene. Analysis of
the mRNA evidenced that the first two nucleotides of
exon 27 (AG) were absent in the dystrophin mRNA of
the DMD patient and a premature STOP codon was
generated. The mechanism we proposed is that in the
presence of the mutated acceptor splice site of intron 26
(AC), the first two nucleotides of intron 27 are recog-
nized as a new acceptor splice site due to sequence
homology and are not included in the mRNA. The elim-
ination of nucleotides AG from exon 27 generates a
STOP codon in exon 27 that does not permit the pro-
duction of a functional dystrophin. The speed with
which diagnosis is given is relevant and determinant to
reduce the anxiety of patients and their family, and to
reduce the recurrence of DMD in the family. Mutation
is necessary not only to confirm the clinical diagnosis
but also enables carrier testing and prenatal diagnosis
for family members [14]. In this case report, evaluation
of the pathogenic effect of the mutation by mRNA ana-
lysis will be useful in the optics of a gene therapy. In
case of an antisense oligonucleotides (AON)-based
approach, specific oligonucleotides are drawn comple-
mentary to the sequence to skip (mutated exons) in
order to inhibit its splicing and to correct the ORF of
the mutated gene. The resulting protein will be partially
functional because it contains both the N- and C-
terminal domains that allow a linkage between the extra-
cellular matrix and the cytoskeleton. In alternative,
AAV-mediated gene replacement therapy or gene editing
approach could be used. Moreover, unrevealing that the
mutation in the acceptor splice site of intron 26 (AG→
AC) caused a premature stop codon in the DMD gene,
evidenced that a therapy based on read-through for non-
sense mutation can be applied to this patient. Read-
through for nonsense mutation is based on administra-
tion of small molecules (like gentamicin and Ataluren)
that are able to introduce a conformational change in
the mRNA structure, thus allowing the ribosomal sub-
units to substitute a mutation-induced stop codon with
a single amino acid [15]. Moreover, on a long term
prospective the mutation analysis paves a base for
phenotypic-genotypic correlation that throws light in
understanding the disorder.
Finally, in dystrophinopathies, not only in DMD, the
creation of a good database will facilitate and accelerate
the inclusion of patients in clinical trials. This underlines
Fig. 2 Functional analysis of DMD mutation. PCR analysis from control and DMD mRNA isolated form peripheral leukocytes was performed in
order to understand if the mutation in the acceptor splice site of intron 26 (AG→ AC) was responsible for uncorrect splicing and abnormal
dystrophin transcript. Both samples control and DMD samples apparently produced a single band of the expected size (exons 25–29) (a). Direct
sequence analyses confirmed that the band obtained by PCR corresponded to the full-length isoform of dystrophin for both control and DMD
samples (b-c). Dystrophin mRNA of the DMD patient was found to miss the first two nucleotides (AG) of exon 27. The mechanism proposed is
that in the presence of the mutated acceptor splice site of intron 26 (AC), the first two nucleotides of intron 27 are recognized as a new acceptor
splice site due to sequence homology and are not included in the mRNA. The elimination of nucleotides AG from exon 27 generates a STOP
codon in exon 27 that do not permit the production of a functional dystrophin (c)
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the importance of setting up national patient registries,
which can contribute to an international database [16].
At now one the best example of such a database is the
TREAT NMD network of excellence (http://www.treat-
nmd.eu/home.php).
Methods
Immunohistological analysis
Muscle biopsies were collected from the biceps brachia-
lis of the DMD patient and of control subjects. This
study was performed according to the guidelines of the
Committee on the Use of Human Subjects in Research
of the Policlinico Hospital of Milan (Milan, Italy) and
the University of Milan. Informed consent was obtained.
Biopsies were frozen in liquid nitrogen and muscle slices
were cut in order to perform Hematoxylin-Eosin (H&E)
staining. Furthermore muscle slices were stained with
three dystrophin antibodies (N-terminal Dys-3 antibody,
C-terminal Dys-2 antibody and Dys-1 antibody;
dilution1/20; NovoCastra, Newcastle-upon-Tyne, United
Kingdom).
Mutation analysis
Blood samples with EDTA were collect from the DMD
patients and a control subject. This study was performed
according to the guidelines of the Committee on the Use
of Human Subjects in Research of the Policlinico Hospital
of Milan (Milan, Italy) and the University of Milan. In-
formed consent was obtained. DNA was isolated from
peripheral leukocytes according to standard salting-out
protocols. DNA was purified using a commercial kit
(E.Z.N.A. Blood DNA Kit II, Peqlab, Erlangen. Germany).
Screening for all exons of the dystrophin gene required
two independent MLPA kits (SALSA P034 and P035) each
with more than 40 individual two-probe sets. MLPA re-
agents were purchased from MRC Holland (Amsterdam).
MLPA experiments were performed following the manu-
facturer’s protocol. Genome sequencing of the DMD gene
was also performed by Primm.
Reverse transcriptase PCR (RT-PCR)
Dystrophic and control RNA was isolated from peripheral
leukocytes using TrizolReagent (Invitrogen, Life Tech-
nologies, Carlsbad, California, USA) as described the man-
ufacturer’s protocol and treated with DNAse-RNAse free
(Promega, Madison, WI, USA). First-strand cDNA was
prepared with the Superscript First Strand-Synthesis Sys-
tem for RT-PCR (Invitrogen Life Technologies), starting
from 1 μg of total RNA and oligo (dT)12–18 priming. PCR
was performed with the following conditions: 94 °C for
5 min, then 30 cycles at 94 °C for 40 s, 60 °C for 40 s, and
72 °C for 1 min. Primers were designed in order to amplify
exon 25–29 of DMD transcript and are listed beneath.
PCR products were run on 1,5 % agarose gel and specific
bands were purified for sequence analysis.
Exon 25: 5′- ATGTGCCAACAGGTCTATGCCAGA -3′:
Exon 29: 5′- TCATCCATGACTCCGCCATCTGTT -3′
Splicing prediction
The sequence obtained by the analysis of the PCR products
referring to DMD sample was analysed using the online
software Alamut 2.0 Splicing Prediction Module in order to
evaluate if a misreading of the splicing site and skipping
of exon 27 happened. (http://www.interactive-biosoftware.
com/doc/alamut-visual/2.6/splicing.html).
Abbreviations
ALT, alanine transaminase; AON, antisense oligonucleotide; AST, aspartate
transaminase; BMD, becker muscular dystrophy; CK, creatine kinase; CMV,
cytomegalovirus; CSA, cross sectional area; dHPLC, denaturing high
performance liquid chromatography; DMD, Duchenne muscular dystrophy;
EVC, Ellis van Creveld syndrome; H&E, hematoxylin-eosin; HR-MCA, high
resolution melting curve analysis; MLPA, multiplex ligation-dependent probe
amplification; MRC, medical research council; NO, nitric oxide; ORF, open
reading frame; PCR, polymerase chain reaction; PTT, protein truncation test;
SSCP, single-strand conformation polymorphism
Funding
The Associazione La Nostra Famiglia Fondo DMD Gli Amici di Emanuele, and
the Associazione Amici del Centro Dino Ferrari.
Authors’ contributions
SM and VA performed the experiments. MM and YT participated in the
design of the study; SM, MM and YT wrote the manuscript.
Competing interests
The authors declare that they have no competing interests.
Ethics approval and consent to participate
This study was approved according to the guidelines of the Committee on
the Use of Human Subjects in Research of the Policlinico Hospital of Milan
(Milan, Italy) and the University of Milan. Unlinked anonymous blood samples
were obtained from the unidentifiable leftover blood of laboratory diagnosis
of dengue infection. According to the guideline of Ministry of Health,
specific consent form was required from the patient.
Received: 8 September 2015 Accepted: 28 July 2016
References
1. Emery AE. Dystrophin function. Lancet. 1990;335(8700):1289.
2. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A,
Kinnett K, McDonald C, Pandya S, et al. Diagnosis and management of
Duchenne muscular dystrophy, part 2: implementation of multidisciplinary
care. Lancet Neurol. 2010;9(2):177–89.
3. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several
proteins, multiple phenotypes. Lancet Neurol. 2003;2(12):731–40.
4. Den Dunnen JT, Grootscholten PM, Bakker E, Blonden LA, Ginjaar HB,
Wapenaar MC, van Paassen HM, van Broeckhoven C, Pearson PL, van
Ommen GJ. Topography of the Duchenne muscular dystrophy (DMD) gene:
FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13
duplications. Am J Hum Genet. 1989;45(6):835–47.
5. Beggs AH, Koenig M, Boyce FM, Kunkel LM. Detection of 98 % of DMD/
BMD gene deletions by polymerase chain reaction. Hum Genet.
1990;86(1):45–8.
6. Nobile C, Galvagni F, Marchi J, Roberts R, Vitiello L. Genomic organization of
the human dystrophin gene across the major deletion hot spot and the 3′
region. Genomics. 1995;28(1):97–100.
7. Oudet C, Hanauer A, Clemens P, Caskey T, Mandel JL. Two hot spots of
recombination in the DMD gene correlate with the deletion prone regions.
Hum Mol Genet. 1992;1(8):599–603.
Meregalli et al. BMC Medical Genetics  (2016) 17:55 Page 5 of 6
8. Mendell JR, Buzin CH, Feng J, Yan J, Serrano C, Sangani DS, Wall C, Prior TW,
Sommer SS. Diagnosis of Duchenne dystrophy by enhanced detection of
small mutations. Neurology. 2001;57(4):645–50.
9. Bennett RR, den Dunnen J, O'Brien KF, Darras BT, Kunkel LM. Detection of
mutations in the dystrophin gene via automated DHPLC screening and
direct sequencing. BMC Genet. 2001;2:17.
10. Ashton EJ, Yau SC, Deans ZC, Abbs SJ. Simultaneous mutation scanning for
gross deletions, duplications and point mutations in the DMD gene. Eur J
Hum Genet. 2008;16(1):53–61.
11. Roest PA, Roberts RG, Sugino S, van Ommen GJ, den Dunnen JT. Protein
truncation test (PTT) for rapid detection of translation-terminating
mutations. Hum Mol Genet. 1993;2(10):1719–21.
12. Almomani R, van der Stoep N, Bakker E, den Dunnen JT, Breuning MH,
Ginjaar IB. Rapid and cost effective detection of small mutations in the
DMD gene by high resolution melting curve analysis. Neuromuscul Disord.
2009;19(6):383–90.
13. Flanigan KM, von Niederhausern A, Dunn DM, Alder J, Mendell JR, Weiss RB.
Rapid direct sequence analysis of the dystrophin gene. Am J Hum Genet.
2003;72(4):931–9.
14. Abbs S, Bobrow M. Analysis of quantitative PCR for the diagnosis of
deletion and duplication carriers in the dystrophin gene. J Med Genet. 1992;
29(3):191–6.
15. Benedetti S, Hoshiya H, Tedesco FS. Repair or replace? Exploiting novel
gene and cell therapy strategies for muscular dystrophies. FEBS J. 2013;
280(17):4263–80.
16. Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den
Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation
database: an overview of mutation types and paradoxical cases that confirm
the reading-frame rule. Muscle Nerve. 2006;34(2):135–44.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Meregalli et al. BMC Medical Genetics  (2016) 17:55 Page 6 of 6
